Logo

Acepodia Reports the US FDA Clearance of IND Application for ACE2016 to Treat Solid Tumors

Share this
Acepodia

Acepodia Reports the US FDA Clearance of IND Application for ACE2016 to Treat Solid Tumors

Shots:

  • The company received the US FDA’s clearance on the IND application submitted for ACE2016 based on the preclinical results depicting the effects of ACE2016 in solid tumor models
  • Following the US FDA’s clearance, Acepodia expects to initiate a P-I FIH trial evaluation the safety, efficacy, tolerability & PD of ACE2016 in patients with locally advanced or metastatic EGFR-expressing solid tumors. The first patient dosing is expected by H2’24
  • ACE2016 is an allogenic γδ2 T cell therapy candidate developed using the company’s proprietary ACC platform to target EGFR-expressing solid tumors through antibody conjugated γδ2 T cells

Ref: PR Newswire | Image: Acepodia

Related News:- AstraZeneca and Daiichi Sankyo Reports sBLA Acceptance with Priority Review by the US FDA for Enhertu to Treat HER2-Expressing Solid Tumors

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions